Cargando…
Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
The SARS-CoV-2 spike trimer is the primary antigen for several serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Until stable cell lines are developed to increase the titer of this secreted protein in mammalian cell culture, the low yield of spike protein p...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265690/ https://www.ncbi.nlm.nih.gov/pubmed/32511418 http://dx.doi.org/10.1101/2020.05.27.120204 |
_version_ | 1783541176928829440 |
---|---|
author | Esposito, Dominic Mehalko, Jennifer Drew, Matthew Snead, Kelly Wall, Vanessa Taylor, Troy Frank, Peter Denson, John-Paul Hong, Min Gulten, Gulcin Sadtler, Kaitlyn Messing, Simon Gillette, William |
author_facet | Esposito, Dominic Mehalko, Jennifer Drew, Matthew Snead, Kelly Wall, Vanessa Taylor, Troy Frank, Peter Denson, John-Paul Hong, Min Gulten, Gulcin Sadtler, Kaitlyn Messing, Simon Gillette, William |
author_sort | Esposito, Dominic |
collection | PubMed |
description | The SARS-CoV-2 spike trimer is the primary antigen for several serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Until stable cell lines are developed to increase the titer of this secreted protein in mammalian cell culture, the low yield of spike protein produced from transient transfection of HEK293 cells will be a limiting factor for these assays. To improve the yield of spike protein and support the high demand for antigens in serology assays, we investigated several recombinant protein expression variables by altering the incubation temperature, harvest time, chromatography strategy, and final protein manipulation. Through this investigation, we developed a simplified and robust purification strategy that consistently yields 5 mg of protein per liter of expression culture for two commonly used forms of the SARS-CoV-2 spike protein. We show that these proteins form well-behaved stable trimers and are consistently functional in serology assays across multiple protein production lots. |
format | Online Article Text |
id | pubmed-7265690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-72656902020-06-07 Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays Esposito, Dominic Mehalko, Jennifer Drew, Matthew Snead, Kelly Wall, Vanessa Taylor, Troy Frank, Peter Denson, John-Paul Hong, Min Gulten, Gulcin Sadtler, Kaitlyn Messing, Simon Gillette, William bioRxiv Article The SARS-CoV-2 spike trimer is the primary antigen for several serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Until stable cell lines are developed to increase the titer of this secreted protein in mammalian cell culture, the low yield of spike protein produced from transient transfection of HEK293 cells will be a limiting factor for these assays. To improve the yield of spike protein and support the high demand for antigens in serology assays, we investigated several recombinant protein expression variables by altering the incubation temperature, harvest time, chromatography strategy, and final protein manipulation. Through this investigation, we developed a simplified and robust purification strategy that consistently yields 5 mg of protein per liter of expression culture for two commonly used forms of the SARS-CoV-2 spike protein. We show that these proteins form well-behaved stable trimers and are consistently functional in serology assays across multiple protein production lots. Cold Spring Harbor Laboratory 2020-05-28 /pmc/articles/PMC7265690/ /pubmed/32511418 http://dx.doi.org/10.1101/2020.05.27.120204 Text en https://creativecommons.org/publicdomain/zero/1.0/This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license (https://creativecommons.org/publicdomain/zero/1.0/) . |
spellingShingle | Article Esposito, Dominic Mehalko, Jennifer Drew, Matthew Snead, Kelly Wall, Vanessa Taylor, Troy Frank, Peter Denson, John-Paul Hong, Min Gulten, Gulcin Sadtler, Kaitlyn Messing, Simon Gillette, William Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays |
title | Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays |
title_full | Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays |
title_fullStr | Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays |
title_full_unstemmed | Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays |
title_short | Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays |
title_sort | optimizing high-yield production of sars-cov-2 soluble spike trimers for serology assays |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265690/ https://www.ncbi.nlm.nih.gov/pubmed/32511418 http://dx.doi.org/10.1101/2020.05.27.120204 |
work_keys_str_mv | AT espositodominic optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT mehalkojennifer optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT drewmatthew optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT sneadkelly optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT wallvanessa optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT taylortroy optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT frankpeter optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT densonjohnpaul optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT hongmin optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT gultengulcin optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT sadtlerkaitlyn optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT messingsimon optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays AT gillettewilliam optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays |